{"filing":{"accession_number":"0001193125-26-232533","cik":"0001527753","ticker":"PSNL","company_name":"Personalis, Inc.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"psnl-20260519.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526232533/psnl-20260519.htm"},"events":[{"id":9790,"run_id":8583,"accession_number":"0001193125-26-232533","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The Centers for Medicare \u0026 Medicaid Services expanded Medicare coverage for Personalis's NeXT Personal® test to include a new clinical indication (monitoring treatment response to neoadjuvant therapy in Stage II-III breast cancer patients). This regulatory approval expands the addressable market and revenue potential for a key product, which is material to investors. However, the event does not fit neatly into more specific categories (not an earnings release, M\u0026A activity, impairment, or litigation), so it is classified as other_material.","company_name":"Personalis, Inc.","ticker":"PSNL","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":588,"accession_number":"0001193125-26-232533","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Centers for Medicare \u0026 Medicaid Services expanded Medicare coverage for Personalis's NeXT Personal® test to include a new clinical indication (monitoring treatment response to neoadjuvant therapy in Stage II-III breast cancer patients). This regulatory approval expands the addressable market and revenue potential for a key product, which is material to investors. However, the event does not fit neatly into more specific categories (not an earnings release, M\u0026A activity, impairment, or litigation), so it is classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:46:35.944446+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":588,"accession_number":"0001193125-26-232533","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Centers for Medicare \u0026 Medicaid Services expanded Medicare coverage for Personalis's NeXT Personal® test to include a new clinical indication (monitoring treatment response to neoadjuvant therapy in Stage II-III breast cancer patients). This regulatory approval expands the addressable market and revenue potential for a key product, which is material to investors. However, the event does not fit neatly into more specific categories (not an earnings release, M\u0026A activity, impairment, or litigation), so it is classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:46:35.944446+00:00","company_name":"Personalis, Inc.","ticker":"PSNL","filing_date":"2026-05-20"}]}